Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis.
Edward LiDylan J MezzioDavid CampbellKim CampbellGary H LymanPublished in: JCO oncology practice (2021)
PP with a biosimilar filgrastim (specifically filgrastim-sndz) is cost-effective in patients with intermediate risk for FN receiving curative chemotherapy regimens for breast cancer, NSCLC, and NHL. Expanding the use of colony-stimulating factors for patients may be valuable in reducing unnecessary health care visits for patients with cancer at risk of complications because of COVID-19 and should be considered for the indefinite future.
Keyphrases
- chemotherapy induced
- healthcare
- end stage renal disease
- prognostic factors
- coronavirus disease
- ejection fraction
- newly diagnosed
- small cell lung cancer
- sars cov
- chronic kidney disease
- peritoneal dialysis
- advanced non small cell lung cancer
- locally advanced
- rectal cancer
- urinary tract infection
- current status
- respiratory syndrome coronavirus
- health insurance
- breast cancer risk
- tyrosine kinase
- patient reported